Lymphoma Clinical Trials in Maryland

Showing 181-200 of 740 trials

A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

NCT04212013

The purpose of this study is to see if the combination of rituximab and ibrutinib can help people with marginal zone lymphoma who have not received treatment in the past. The study will also compare the combination of rituximab and ibrutinib with the combination of rituximab and placebo to see which combination works better.

Marginal Zone Lymphoma

Memorial Sloan Kettering Cancer Center23 participantsStarted Dec 2019

Washington D.C., District of Columbia, United States • Tampa, Florida, United States • Rochester, Minnesota, United States +7 more locations

COMPLETEDPhase 1/217 miles

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

NCT02956382

This is a phase I/II study in which patients will be enrolled in a standard 3+3 design. Once the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory grade 1-3a follicular lymphoma, there will be a 17-patient phase II study.

Refractory Follicular LymphomaRelapsed Follicular Lymphoma

Georgetown University24 participantsStarted Mar 2017

Washington D.C., District of Columbia, United States • Hackensack, New Jersey, United States • Seattle, Washington, United States

A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Lymphoma Trials in Other Cities

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

EchoTip AcuCore Post-Market Clinical Study

A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma

Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies

BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Other Conditions in Maryland